Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New anxiety pill shows promise in Late-Stage trial

NCT ID NCT06741228

Symptom relief Sponsor: Definium Therapeutics US, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This phase 3 study tests whether an oral medication called MM120 can reduce anxiety symptoms in adults with generalized anxiety disorder. About 214 participants will receive either MM120 or a placebo for 12 weeks, followed by a 40-week period where everyone can receive MM120. The main goal is to see if MM120 lowers anxiety scores on a standard rating scale.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

214 people

The number who actually took part.

Started

Dec 2024

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of GAD per DSM-5 2. Male or female aged 18 to 74 3. HAM-A Total Score ≥20 Exclusion Criteria: 1. Certain psychiatric disorders (other than generalized anxiety disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine) 4. Any clinically significant unstable illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Generalized anxiety disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Generalized anxiety disorder

Contacts and locations

Locations

  • Adams Clinical Boston

    Boston, Massachusetts, 02116, United States

  • Adams Clinical Bronx

    The Bronx, New York, 10461, United States

  • Adams Clinical Dallas

    DeSoto, Texas, 75115, United States

  • Adams Clinical Harlem

    New York, New York, 10029, United States

  • Adams Clinical Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Adams Clinical Watertown

    Watertown, Massachusetts, 02472, United States

  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30331, United States

  • Austin Clinical Trial Partners

    Austin, Texas, 78737, United States

  • BioBehavioral Research of Austin

    Austin, Texas, 78759, United States

  • Cedar Clinical Research

    Draper, Utah, 84020, United States

  • CenExel iResearch, LLC

    Savannah, Georgia, 31405, United States

  • Cleveland Clinic Lutheran Hospital

    Cleveland, Ohio, 44113, United States

  • Clinical Neuroscience Solutions Inc.

    Jacksonville, Florida, 32256, United States

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee, 38119, United States

  • Coastal Carolina Research Center

    North Charleston, South Carolina, 29405, United States

  • FutureSearch Trials of Dallas, LLC

    Dallas, Texas, 75231, United States

  • Hassman Research Institute

    Marlton, New Jersey, 08053, United States

  • Inner Space Research

    Orem, Utah, 84058, United States

  • Kadima Neuropsychiatry Institute

    La Jolla, California, 92037, United States

  • Lighthouse Psychiatry

    Gilbert, Arizona, 85234, United States

  • Memory Clinic Inc.

    Bennington, Vermont, 05201, United States

  • Mountain View

    Denver, Colorado, 80209, United States

  • New York State Psychiatric Institute (NYSPI)

    New York, New York, 10032, United States

  • Psychedelic Science Institute

    Santa Monica, California, 90404, United States

  • Scottsdale Research Institute

    Scottsdale, Arizona, 85022, United States

  • Scranton Medical Institute

    Moosic, Pennsylvania, 18507, United States

  • Seattle Neuropsychiatric Treatment Center

    Seattle, Washington, 98104, United States

  • Segal Trials

    Lauderhill, Florida, 33319, United States

  • Spectrum Neuroscience and Treatment Institute

    New York, New York, 10021, United States

  • Summit Headlands LLC

    Portland, Oregon, 97210, United States

  • UCSF Department of Neurology

    San Francisco, California, 94158, United States

  • University of Texas at Austin

    Austin, Texas, 78712, United States

  • Uptown Research Institute

    Chicago, Illinois, 60640, United States

  • iResearch Atlanta

    Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.